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ABSTRACT
Objectives Kidney cancer has been identified as a 
disease for which screening might provide significant 
benefit for patients. The aim of this study was to 
understand in detail the facilitators and barriers towards 
uptake of a future kidney cancer screening programme, 
and to compare these across four proposed screening 
modalities.
Design An online survey including free- text responses.
Setting UK
Participants 668 adults
Primary and secondary outcome measures The survey 
assessed participants’ self- reported intention to take- up 
kidney cancer screening with four different test methods 
(urine test, blood test, ultrasound scan and low- dose 
CT). We conducted thematic analysis of 2559 free- text 
comments made within the survey using an inductive 
approach.
Results We identified five overarching themes that 
influenced screening intention: ‘personal health beliefs’, 
‘practicalities’, ‘opinions of the test’, ‘attitudes towards 
screening’ and ‘cancer apprehension’. Overall, participants 
considered the tests presented as simple to complete and 
the benefits of early detection to outweigh any drawbacks 
to screening. Dominant facilitators and barriers varied 
with patterns of intention to take up screening across the 
four tests. Most intended to take up screening by all four 
tests, and for these participants, screening was seen as 
a positive health behaviour. A significant minority were 
driven by practicalities and the risks of the tests offered. A 
smaller proportion intended to reject all forms of screening 
offered, often due to fear or worry about results and 
unnecessary medical intervention or a general negative 
view of screening.
Conclusions Most individuals would accept kidney 
cancer screening by any of the four test options presented 
because of strong positive attitudes towards screening 
in general and the perceived simplicity of the tests. 
Providing information about the rationale for screening in 
general and the potential benefits of early detection will be 
important to optimise uptake among uncertain individuals.
INTRODUCTION
Kidney cancer is the ninth most common 
cancer worldwide in men and the 14th most 
common cancer in women,1 with over 400 000 
new cases being diagnosed in 2018.2 The inci-
dence of kidney cancer in the UK is projected 
to rise by 26% between 2014 and 2035, repre-
senting one of the fastest accelerating cancers 
within that timeframe.3 Nearly, a quarter of 
individuals diagnosed with kidney cancer in 
the UK have evidence of metastatic disease 
at presentation;4 the 5- year age- adjusted rela-
tive survival is 86% for those diagnosed with 
the earliest stage of the disease, but drops to 
12% for metastatic disease. These epidemio-
logic data have led to increasing interest in 
screening for kidney cancer, with the devel-
opment of a suitable screening programme 
being identified as a key research priority.5
For a screening programme to be successful, 
it must be acceptable to the general public 
and uptake must be high. Previous research in 
the context of other screening programmes 
has identified a number of factors influ-
encing screening uptake. These include 
practical barriers, for example, difficulty in 
Strengths and limitations of this study
 ► The free- text nature of the questions allowed par-
ticipants to provide their own reasoning without be-
ing prompted or constrained by a list of predefined 
options.
 ► The large sample size meant that we were able 
to explore reasons for both intending to take up 
screening and for not taking up screening.
 ► Our use of an online recruitment platform means the 
views of those who completed our survey may not 
be representative of the general population.
 ► It also meant we relied on written comments from 
participants and were unable to explore their com-
ments or views in- depth.
 ► In the absence of an existing screening programme, 
we were also only able to assess reasons behind 
intention and not attendance at screening.
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making an appointment or lack of time to do so,6 7 as well 
as psychosocial barriers such as fear or embarrassment.7–9 
Identified facilitators of screening attendance encompass 
both societal factors such as public education, physician 
recommendation and social networks,10 11 and personal 
factors such as positive attitudes towards screening,12 the 
desire for peace of mind9 13 and subjective assessments 
of individual health status and cancer risk.11 14 However, 
many of these existing studies have identified public 
opinion through qualitative methods with small sample 
sizes, or via surveys using predefined lists of possible 
responses. Furthermore, these studies have focused on 
cancers for which there are existing national screening 
programmes (breast, cervical and colorectal cancer). 
Compared with these cancers, kidney cancer has a lower 
prevalence,3 public awareness of the condition is lower,15 
and the range of potential screening modalities is greater. 
Understanding the specific reasons why people intend to 
take up or decline kidney cancer screening with different 
screening tests is therefore important when developing 
future kidney cancer screening programmes.
In an online survey, we have shown that a future 
kidney cancer screening programme would be positively 
received and intention to attend high, while the choice of 
screening test is likely to have an important influence on 
uptake.16 The aim of the current study was to use free- text 
responses to questions in the online survey to describe the 
reasons for intending to accept or decline kidney cancer 
screening with four different putative screening test 
options (urine dipstick analysis, blood based biomarkers, 
low dose CT and ultrasound). The free- text responses 
are used to understand in detail the reasons for those 
findings, identify the specific barriers and facilitators for 
kidney cancer screening and to compare these drivers 
across four proposed screening modalities.
METHODS
Study design
This study reports analysis of free- text answers from an 
online population- based survey of 668 members of the 
public in the UK aged 45–77 years.
Participants and recruitment
Participants were recruited to complete the survey 
through an online participant recruitment platform for 
researchers (Prolific, www. prolific. ac). Individuals regis-
tered with Prolific were eligible to take part if they were 
between 45 and 79 years old and had a Prolific approval 
rating ≥95% (reflecting the percentage of studies 
completed that have been approved by researchers). The 
survey was added to the Prolific platform on 20 August 
2019. At that time, 7767 met the eligibility criteria for 
the study. Based on demographic data available on the 
Prolific website, approximately 80% of these were White/
Caucasian, 34% male, 53% lived in the UK, 15% were 
current smokers, 43% had a university level education 
and 51% considered themselves to be in the top five 
deciles of socioeconomic status. The survey was live for 
8 hours. During this time, 1190 participants viewed the 
participant information leaflet and consent form. A total 
of 1021 participants completed the survey. The analysis 
reported here is based on the free- text comments from 
the 668 UK- based participants. We chose to limit to UK 
participants for this analysis to remove any differences in 
views arising from cultural differences in attitudes towards 
cancer, screening and different healthcare or insurance 
systems.
Survey
A copy of the relevant sections of the survey can be found 
in online supplemental file 1. In brief, after providing 
basic demographic data, participants were presented 
with an overview of kidney cancer, and then the details 
of four potential screening methods (urine testing, blood 
biomarkers, low- dose CT and ultrasound). This informa-
tion included the number of people likely to test positive 
with each test method, and of those, how many people 
would actually have cancer. These summaries were devel-
oped in collaboration with patient and public represen-
tatives, based on the best available evidence, and the 
information was reviewed by two urologists within the 
research team (GDS and SHR). Following presentation 
of the details of the screening methods, participants were 
asked how likely they would be to take part in screening 
with each method (response options were ‘Very likely’, 
‘Likely’, ‘Unlikely’ and ‘Very unlikely’). Participants were 
subsequently asked to ‘describe in a few words why?’ they 
had given that response for each screening modality. This 
analysis focuses on the free- text responses to those four 
open- ended questions.
Qualitative analysis
We conducted thematic analysis of all free- text 
comments using an inductive approach, with initial 
coding of responses being driven by the content of 
the comments themselves. Responses were analysed in 
two groups based on whether participants responded 
positively (‘likely’ or ‘very likely’ to take part) or nega-
tively (‘unlikely’ or ‘very unlikely’ to take part). From 
this point, these groups will be referred to as ‘likely’ 
or ‘unlikely’, respectively. During the analysis process, 
comments that were inconsistent with the partici-
pant’s previous answer were removed (eg, if they 
answered ‘very unlikely’ to take part but provided a 
free- text answer supporting screening). Incomplete 
data (where participants did not provide any free 
text) were also removed.
Two researchers (KM, a researcher with qualitative 
expertise and CF- S a medical student with a qualitative 
research background) familiarised themselves with a 
random sample of 400 comments, representing 15% 
of the total data and equally split between those likely 
or unlikely to take part, and developed initial codes 
independently. They then discussed and reviewed the 
coding decisions and developed two consolidated lists: 
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one for the ‘likely’ to take part comments, and one for 
the ‘unlikely’ to take part comments (figure 1). The 
remaining free- text comments were coded into these 
agreed lists within an excel file by one researcher 
(CF- S). If a comment contained multiple meanings, 
the comment was assigned to as many codes as appro-
priate to cover the content. At this stage, 5% of the 
total sample, selected at random, was coded by two 
researchers (CF- S and LH- K) and any discrepancies 
discussed. Agreement between the two was 94%. The 
full list of codes was then discussed at a meeting with 
the entire research team. Within this meeting, the 
group mapped the individual codes into overarching 
themes.
To compare the relative importance of individual codes 
and themes, the number of times a code was mentioned 
for each of the four screening tests was counted. We used 
this data first to explore differences in responses between 
screening modalities, descriptively highlighting the differ-
ences in code frequencies. We then divided participants 
into three subgroups: those likely to take up screening by 
all four test methods, those unlikely to take up screening 
by any of the methods and those whose intention varied 
between the tests. Differences in the patterns of responses 
between these groups were explored. Finally, we inves-
tigated the patterns of responses with sex, age, level of 
education and social group.
Ethics approval and consent to participate
Ethical approval was obtained from the Psychology 
Research Ethics committee of the University of Cambridge 
Figure 1 Individual codes (facilitators and barriers) mapped onto overarching themes.
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(Ref 2019.055). All participants gave informed written 
online consent before they began the survey.
Patient and public involvement
Two members of the public contributed, through face- 
to- face discussions and email, to the development of 
the survey and participant information sheet. They also 
provided comments on the final manuscript prior to 
submission.
RESULTS
The sociodemographic profile of the sample is shown in 
table 1. 373 (54%) were female, with a mean age of 54.7±7 
years and a good distribution across age groups. Most 
(73%) participants were in social group ABC1 (those with 
managerial, administrative or professional job roles) and 
288 (43.1%) had university level education.
Intention to take up kidney cancer screening
Overall, the majority of participants (518, 78%) were likely 
to take up screening by all four screening test modalities. 
Of the remaining participants, 119 (18%) would be likely 
to take up some screening tests but not all, with 55/119 
(46%) likely to attend for an ultrasound, urine or blood 
testing, but not for a low- dose CT scan. 31 (5%) indicated 
that they were unlikely to take up screening by any of 
the test methods. Since intention to take- up screening 
was high, we collected a greater number of free- text 
comments relating to reasons why someone was likely to 
take part in screening. Once inconsistent and blank data 
had been removed (51 and 62 participants, respectively), 
there were 2304 comments from those ‘likely’ to take up 
screening and 255 comments from those ‘unlikely’ to 
take up a screening.
Themes identified
From the free- text comments, we identified 49 individual 
codes (27 facilitators and 22 barriers from those likely and 
unlikely to take up screening, respectively). On average, 
each comment was coded under 1.5 codes: 1448 (56.6%) 
of comments were relevant to one code, 907 (35.4%) 
were relevant to two codes, with the remaining 204 (8%) 
relevant to three or more. Together, the codes mapped 
onto five overarching themes (figure 1): personal health 
beliefs; cancer apprehension; attitudes towards screening; 
opinions of the test and practicalities (additionally, we 
included an ‘other’ category containing five codes that 
did not map elsewhere). Illustrative quotes from each 
theme are presented in table 2.
Facilitators and barriers identified across screening methods
Table 3 shows the frequency with which each of the 
facilitators and barriers were reported, overall and 
across the four screening modalities. 648 participants 
provided comments relating to blood tests. 589 (91%) 
of those were likely to attend. Comments among 
that group focused primarily on statements that 
blood testing is ‘simple to complete’ (160, 25%), the 
‘benefits of screening outweigh the drawbacks’ (84, 
13%) and ‘early detection is a benefit’ (73, 11%). Of 
those unlikely to take up blood testing (59, 9%), the 
only consistently mentioned barrier was a ‘dislike of 
the test method’, mentioned by 3% (21).
Among the 637 participants providing comments 
on urine testing, 608 (95%) were likely to take 
Table 1 Participant characteristics
UK (n=668)



















Excellent, very good, good 524 (78)
Fair, poor 144 (22)
Smoking
Non- smoker 340 (51)
Ex- smoker 236 (35)
Current smoker 92 (14)
BMI
Mean (SD) 27.4 (5.8)
Range 16.5–50.0
Missing 29 (4)
Previous diagnosis of cancer?
Yes 34 (5)
No 634 (95)








BMI, body mass index.
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up screening. Similar to the responses for blood 
testing, the most common overall reason for taking 
up screening was that the test is ‘simple to complete’ 
(282, 44%). Frequently cited other comments that 
related specifically to the characteristics of the test 
were ‘little or no inconvenience’ (79, 12%) and 
‘quick’ (57, 9%). ‘Early detection is a benefit’ was 
also frequently mentioned by this group (63, 10%) 
but references to ‘benefits of screening outweigh the 
drawbacks’ were less common, potentially reflecting 
that fewer drawbacks are associated with urine testing 
than blood testing. Overall, no single barrier to urine 
testing was identified, with no code occurring more 
than six times.
631 participants provided comments relating to 
ultrasound scans and 643 relating to CT. Intention 
to take up screening was again high with 575 (91%) 
likely to attend ultrasound and 532 (82%) CT. 
Notably, among participants likely to accept screening 
by ultrasound or CT, the most mentioned facilitator 
for both does not relate to the test itself but the 
belief that ‘early detection is a benefit’ (97 (15%) for 
CT scan, 107 (17%) for ultrasound). Although less 
dominant, ‘simple to complete’ was still mentioned 
for both (55 (9%) for CT, 80 (13%) for ultrasound). 
For ultrasound, there are also multiple codes within 
the theme ‘opinions of the test’ that are mentioned 
more frequently than for other test methods: ‘pain-
less’ (57, 9%) ‘non- invasive’ (53, 8%) and ‘without 
risks’ (46, 7%). Of these facilitators, only ‘painless’ 
is mentioned with some frequency for CT scans (45, 
7%). As seen for blood tests, ‘benefits of screening 
outweigh the drawbacks’ is also a dominant facilitator 
for CT scans.
The key barrier identified by those unlikely to take 
up a CT scan is the ‘risk of the test’ (53, 8%), some 
mentioning only concerns regarding the danger 
of radiation, while others linked this to long term 
cancer risks. An additional barrier highlighted for 
both CT and ultrasound, but not blood or urine 
testing, was travel to a hospital (10 (2%) and 9 (1%) 
respectively).
Notably, across all test modalities and across those 
likely or unlikely to attend screening, there were very 
few comments that related to the risk of kidney cancer 
specifically or the accuracy or relative costs of the 
tests. Evaluation of the responses by demographics 
also revealed no clear patterns with age, sex, social 
group or university education.
Table 2 Illustrative quotes of themes
Qualitative theme Barriers: illustrative quotes Facilitators: illustrative quotes
Personal health beliefs ‘I have a healthy lifestyle and at a low risk for 
kidney cancer’. (F, 55–59 years, ultrasound)
‘There is no kidney cancer or cancer in my 
immediate family’. (F, 45–49 years, blood test)
‘As my parent had kidney cancer, I would very 
much put myself forward to screening’. (F, 60–64 
years, ultrasound)
‘Because life is precious, I want to live as long as 
possible’. (M, 55–59 years, CT)
Practicalities ‘Because my mobility problems make it very 
difficult for me to travel anywhere’. (F, 55–59 
years, ultrasound)
‘If it involved a specific visit, it’s unlikely I would 
want to go’. (M, 55–59 years, urine test)
‘It’s no inconvenience at all to have any of the 
screening methods discussed’. (M, 50–54 years, 
urine test)
‘I have had ultrasound scans before, its quick and 
easy’ (F, 45–49 years, ultrasound scan)
Opinions of the test ‘I would not wish to receive a dose of radiation 
to test for the extremely small chance of kidney 
cancer’. (M, 65–69 years, CT)
‘Really don't like needles, I'd opt for something 
else if it were available’. (M, 45–49 years, blood 
tests)
‘A simple procedure and blood tests don't really 
alarm me at all’. (M, 70–74 years, blood test)
‘Easy to do when attending the doctors for 
something else and not painful in anyway’. (F, 
50–54 years, urine test)
Attitudes towards 
screening
‘Generally, I do not like medical appointments 
unless I need treatment’. (M, 55–59 years, blood 
tests)
‘There are a lot of cancers, you can’t screen for all 
of them. If I had symptoms, I would see a GP’. (F, 
50–54 years, ultrasound)
‘Benefit of early detection outweighs minor 
inconvenience of screening’ (M, 55–59 years, 
blood test)
‘Would be foolish not to. If the disease has 
no symptoms and can be identified through 
screening, has the potential to save lives’. (F, 
55–59 years, CT)
Cancer apprehension ‘I would be too afraid of the results. Short of 
a transplant, what could be done anyway?’ (F, 
55–59 years, urine test)
‘The stress of going to the hospital waiting for 
results is too great’. (F, 60–64 years, CT)
‘Why waste a chance to “set nerves at rest”?’ (M, 
55–59 years, blood test)
‘High value of early detection or peace of mind’ 
(M, 50–54 years, blood test)
F, female; M, male.
6 Freer- Smith C, et al. BMJ Open 2021;11:e044961. doi:10.1136/bmjopen-2020-044961
Open access 
Table 3 Facilitators and barriers of screening uptake across modalities, frequency of mention of codes and themes
Themes Individual codes
Blood Urine CT USS Total Theme 
totaln=589 n=608 n=532 n=575 n=2304
Personal health 
beliefs
Life extending/improved survival 34 34 54 48 204 224
Family history of cancer 2 1 2 3 9
Risk of kidney cancer 0 1 2 7 11
Practicalities Simple to complete 160 282 55 80 859 1468
Little or no inconvenience 38 79 26 32 254
Test can be conducted at GP 22 32 0 4 90
Quick 42 57 32 43 231
Cost effective 8 10 4 2 34
Opinions of the 
test
Painless 18 26 45 57 172 803
Test non- invasive 6 23 27 53 132
Test is without risks 21 23 23 46 136
Comfortable having test 52 17 17 23 126
Have had test before 34 15 20 39 123
Effective test 25 24 14 13 100
Low radiation 0 1 10 2 14




Early detection is a benefit 73 63 97 107 403 928
Detection for better tx/more tx 
options
16 16 25 25 98
Sensible 42 44 54 73 257
For my general health/good 22 18 41 39 138
As part of other normal health 
checks
15 6 3 2 32
Want all screening/tests available 41 34 47 52 208
Benefits of screening outweigh 
the drawbacks
84 13 72 28 210
Cancer 
apprehension
Want to detect cancer 48 35 41 54 213 485
Peace of mind/reassurance 46 43 66 74 272
Other General agreement 32 22 25 15 116 129
Influence of HCP 
recommendation
3 1 4 4 13
  Blood Urine CT USS Total Theme 
total
n=59 n=29 n=111 n=56 n=255
Personal health 
beliefs
No family history of cancer 1 1 1 1 5 50
Perceived good health 2 2 0 2 8
No concern for kidney cancer 2 3 3 6 17
Believe themselves to be low risk 2 1 2 6 12
Other health concerns more 
important
1 1 2 3 8
Practicalities Inconvenience 3 3 7 4 20 43
Do not want to travel to hospital 2 1 10 9 23
Continued
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Subgroup thematic analysis
Comparison of the comments made by participants who 
said they were likely to take up screening by all four test 
methods with those who would accept screening by some 
of the test methods only is presented in table 4. For those 
whose likelihood of taking up screening varied between 
the different tests, ‘practicalities’ and ‘opinions of the 
test’ remained the most prominent themes. ‘Simple to 
complete’ represented the most frequently mentioned 
individual code (41%, n=118/290 comments), with most 
of these from comments in relation to urine or blood 
testing. The non- invasive nature of ultrasound scanning, 
and perceived lack of risks associated with this test were 
also seen in this group.
Conversely, for participants who would accept 
screening with all four tests, the themes ‘attitudes towards 
screening’, ‘cancer apprehension’ and ‘personal health 
beliefs’ are proportionally more important. While ‘simple 
to complete’ is still the most mentioned individual code, 
others within these additional themes become equally 
important. The facilitators identified within the ‘atti-
tudes towards screening’ theme reflect a general attitude 
that screening is a ‘correct’ form of behaviour: ‘sensible’ 
(10%, n=200/2014 comments), ‘for my general health/
good’ (6%, n=115/2014), ‘early detection is a benefit’ 
(16%, n=323/2014 comments). The perceived benefits 
of early detection that were highlighted by participants 
included improved survival, better treatment and more 
treatment options. Many participants, however, simply 
stated that early detection is always beneficial and did 
not give further explanation. Another common belief 
described by this group was the idea that screening could 
provide a sense of ‘peace of mind/reassurance’ that they 
did not have the disease (11%, n=219/2014), highlighting 
one way in which cancer worry can motivate screening 
attendance.
Table 5 shows the barriers cited by those who are 
unlikely to take up screening by any of the tests and those 
whose attitude towards screening varied with screening 
modality. For those declining some test methods, but not 
all, the only dominant theme is ‘opinions of the test’: 
most of these comments reference the ‘risks of the test’ 
for CT scan (54%, 45/84), or a ‘dislike of the test’ for 
blood tests (59%, 19/32). Very few other barriers outside 
of these are mentioned. In contrast, those who decline 
all screening methods do not mention test specific 
concerns, instead ‘attitudes towards screening’, ‘personal 
health beliefs’ and ‘cancer apprehension’ are all more 
frequently raised across all the test modalities. The most 
frequently mentioned individual barrier to screening is 
‘worry/fear about results’ (17%, 18/109). Many also state 
that they ‘do not want any screening’ (15%, 16/109) or 
Themes Individual codes
Blood Urine CT USS Total Theme 
totaln=589 n=608 n=532 n=575 n=2304
Opinions of the 
test
Dislike test method (general) 21 1 9 1 33 124
Painful 3 0 0 1 4
Invasive test 3 0 0 0 3
Risks of the test 1 0 53 1 55
Would have other testing first 2 0 11 2 15
Concern regarding inaccurate 
results




Medical care for diagnosis/ 
symptoms only
4 4 7 6 25 70
Potential to lead to further tests 1 3 1 0 8
Not a good use of NHS resources 2 2 4 2 12
Do not want any screening 4 4 4 9 25
Cancer 
apprehension
Worry/fear about the results 6 6 6 7 31 53
General fear 5 2 7 6 22
Other General negative comment 4 0 5 3 12 36
Concerns regarding medical 
profession
2 1 3 3 10
Beliefs about treatment of kidney 
cancer
4 2 4 2 14
The colour gradients shown indicate where each value falls within the range of data shown calculated within either the 
facilitator, or the barrier data set
GP, general practitioner; HCP, healthcare professional; NHS, National Health Service; tx, treatment.; USS, ultrasound scan.
Table 3 Continued
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they believe that that ‘medical care is for diagnosis/symp-
toms only’ (14%, 15/109), reflecting a disagreement with 
the principle of screening in general.
DISCUSSION
Key findings
Through a thematic analysis of over 2000 free- text 
comments from an online survey, we have identified, 
and ranked the relative importance of, facilitators 
and barriers influencing potential uptake of kidney 
cancer screening by four possible screening modali-
ties in a UK population. We found that, overall, across 
all four tests most participants considered screening 
simple to complete and that the benefits of early 
detection outweigh any burdens or harms. Urine 
testing was viewed as the simplest and least invasive to 
complete; without the risks or inconvenience associ-
ated with other tests. Additionally, we found that the 
dominant drivers and barriers varied with patterns of 
intention to take up screening across the four tests. 
The most frequent pattern, and therefore the largest 
group of individuals, was those who were likely to take 
up screening with all four tests. Among this group, 
screening was seen as a positive health behaviour, with 
many benefits: the tests are seen as simple, they see 
early detection as an advantage, or seek the peace of 
mind and clarity that accompanies a negative screening 
result. The second group was those for whom the 
specific test modality influences decision making. 
Within this group, a significant minority would attend 
all tests except for a CT scan, due to concern about 
the risk associated with a CT. Blood tests also pola-
rised participants: most were comfortable with this 
method and it was seen as simple by many, but a small 
minority expressed a specific dislike of blood tests. 
Having to travel to hospital for a CT or USS also put 
some people off these modalities. The smallest group 
was those who reject all forms of screening. For these 
individuals, the drawbacks of screening in general are 
highlighted rather than opinions related to specific 
tests. These drawbacks include fear or worry about 
results and unnecessary medical intervention and are 
not balanced by sufficient benefits. Notably, largely 
absent from the reasons that participants did or did 
not intend to take up screening among any of these 
groups were comments related to the accuracy of the 
tests or the risk of kidney cancer specifically, despite 
information on both of these being included within 
the survey.
Comparison with existing literature
Our finding that the decision to take up screening 
in this study for many of the participants was driven 
by the perceived value of early detection, with 
screening embodying a positive health behaviour 
(or a sensible decision) is consistent with previous 
studies exploring facilitators of screening in existing 
cancer screening programmes10 11 13 17–19 and the view 
that screening is ‘almost always a good idea’.20 Our 
study builds on these findings by showing that these 
beliefs about screening extend to hypothetical new 
screening programmes and, for the individuals who 
hold these views, the nature of the screening test is 
not a key factor in their decision of whether to take 
up screening or not. This observation, that screening 
decisions are often driven by emotions and strongly 
held contextual beliefs, was also seen among those 
who did not intend to attend screening with any of 
the tests. While a small number of participants in this 
group appear to have been consciously weighing up 
the potential benefits and harms of kidney cancer 
screening within the context of their own personal 
health beliefs, our findings suggest many may be 
driven by a more general aversion to the concept of 
screening or apprehension about cancer in general or 
the results. This has been reported in the context of 
other screening programmes12 21–25 and highlights the 
need for information materials to clarify the purpose 
of screening and advantages of early diagnosis in 
asymptomatic individuals22 and to specifically address 
negative beliefs around the disease and cancer worry. 
The preference for simple and convenient tests, seen 
through the responses for urine and blood testing 
in particular in this study, has also been reported 
previously in the context of other cancer screening 
programmes.7 14 26 Our findings additionally show that 
the risks associated with exposure to radiation for CT 
are a key barrier for some individuals.
Strengths and limitations
The main strengths of this study are the large sample size 
and the free- text nature of the questions that allowed 
participants to provide their own reasoning without being 
prompted by a list of predefined options.
The large sample size meant that we were able to 
explore reasons for not taking up screening among 
the minority of participants who would be unlikely 
to take it up. Uptake rates for UK cancer screening 
programmes are consistently below 75%,27–29 there-
fore, capturing the perspectives of those who are less 
likely to accept screening (and difficult to engage in 
research) is important. Since we were also only able to 
assess the reasoning behind the participants’ intention 
to attend screening, and not their actual attendance, 
this highlights a limitation of our study, as intention 
may be higher than attendance. We also relied on the 
written comments and were unable to go back to indi-
viduals for clarification or further in- depth explora-
tion of their views.
As a result of our use of an online recruitment 
method, the views of those who completed our 
survey may also not be representative of the general 
population.30 In particular, the distribution across 
social groups was different: 73% of our participants 
reported being in the upper half of the social grades 
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(ABC1), whereas census data from 2011 suggest 53% 
of the UK population lies within this category. Given 
that participation in screening programmes is dispro-
portionately lower among lower social grades,19 31 
the participants in our study may, therefore, be more 
enthusiastic about screening than the UK population 
as a whole. National screening programmes for cancer 
are also established within the UK and provided at no 
cost to participants within a state funded healthcare 
system. Awareness of these government programmes 
and the absence of cost as a barrier may have influ-
enced the participants views. There are also known 
cultural variations in attitudes towards cancer and 
awareness of cancer risk that may influence response 
to screening.32 33 While we would expect the range of 
attitudes to be similar in other countries, the relative 
frequency of the individual codes and themes may 
therefore differ. With online data collection, there is 
also the risk that participants did not concentrate and 
their responses do not accurately reflect their views. 
We sought to limit this by including an instructional 
manipulation check early on the questionnaire. Only 
51 of the 2559 comments (1.9%) were also incon-
sistent, suggesting that the overwhelming majority 
of participants were appropriately engaged with the 
survey.
The free- text nature of the questions meant that 
participants were free to express their thoughts in their 
own words. This has the advantage of not constraining 
them by predefined lists. However, the question we 
asked (‘Please describe in a few words why?’) did not 
instruct participants to list all the reasons behind their 
choice, meaning responses ranged from one word to 
several sentences. Our findings, therefore, reflect the 
dominant views of participants when faced with the 
option of a given screening test, not all their views. 
The relative frequency of the different codes and 
themes reflects their importance and not the neces-
sarily the number of participants for whom that factor 
may contribute to their decision.
CONCLUSIONS
Our findings show that most individuals in a UK popu-
lation think they are likely to attend kidney cancer 
screening by any of the four test options presented. 
These individuals are driven both by a general percep-
tion of screening as a good thing and the view that 
the tests are simple, making them likely to participate 
in any future kidney cancer screening programme 
largely without consideration of the nature of the 
test involved or their own risk of kidney cancer. For 
the significant minority for whom the practicalities 
and risks of the tests are important, optimising the 
logistics of the screening programme and ensuring 
that the written information is understandable, for 
example around the radiation risk associated with CT, 
will be important. Providing sufficient information to 
enable individuals to make an informed choice about 
screening will also be important for the small propor-
tion of the population who do not intend to take up 
screening with any of the test options. Our findings 
suggest that that information should not be limited 
to the specific details of kidney cancer screening but 
should also include an explanation of the rationale 
for screening in general and the potential benefits of 
early detection.
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